A Phase 3 interventional study of Rivaroxaban, 10 mg and Rivaroxaban, 7.5 mg in Heart Failure, Respiratory Insufficiency and Stroke Acute, sponsored by Janssen Research & Development, LLC. Completed at 617 sites in 37 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Heart Failure by Johnson & Johnson — 3 open to participants now, 5 under way, none of them phase 3. Heart Failure · Johnson & Johnson.
Among the 42 studies in Heart Failure by Johnson & Johnson, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 28th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →3 of the 42 studies in Heart Failure by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
Abiomed Inc. · Sites in Germany
Ages 18+
V-Wave Ltd
Ages 18+
By country, each count listing its studies:
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 12 · Phase 4 1
First in 1996; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12,024 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 91 across the 33 interventional studies, 918 across the 8 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Heart Failure by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for venous thromboembolism (VTE). The study is designed to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge. The study will consist of a screening phase, a 45-day double-blind treatment phase, and a 30-day follow-up phase. Study drug will start at randomization (Day 1), and will continue until Day 45 (inclusive). A total of approximately 12000 patients will be randomly assigned to either rivaroxaban or placebo in a 1:1 ratio. The total duration for a patient who completes the study after randomization is expected to be 75 days.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
Drug: Rivaroxaban, 10 mg · Drug: Rivaroxaban, 7.5 mg
Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
Drug: Placebo
Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
Also known as: Xarelto, BAY59-7939
Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
Also known as: Xarelto, BAY59-7939
All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)
Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Time frame: Up to Day 45
Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC
A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days.
Time frame: From randomization to 2 days after the last dose (Day 45)
Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC
Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Time frame: Up to Day 45
Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC
Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Time frame: Up to Day 45
Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Time frame: Up to Day 45
Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Time frame: Up to Day 45
Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC
Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Time frame: Up to Day 45
12024 participants were randomized (rivaroxaban-6007;placebo-6017). 5 participants in placebo were excluded(2 invalid consent,3 randomized before Health Authority approval).
| Milestone | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Started | 6007 | 6012 |
| Treated | 5982 | 5980 |
| Completed | 5876 | 5869 |
| Not completed | 131 | 143 |
| Withdrew: Death | 109 | 120 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Withdrawal by subject | 20 | 20 |
Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC) | 0.84 | 1.11 |
A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC | 0.28 | 0.15 |
Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC | 0.72 | 0.77 |
Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC | 0.19 | 0.42 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC | 1.31 | 1.80 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC | 1.58 | 2.03 |
Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
| Events per 100 participants in 45 days | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC | 1.19 | 1.49 |
Collected over Up to 75 days (+/-5 days). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 115/6,007 (1.9%) | 475/6,007 (7.9%) | 250/6,007 (4.2%) |
| Placebo | 126/6,012 (2.1%) | 493/6,012 (8.2%) | 280/6,012 (4.7%) |
| Event | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 81/6007 | 77/6012 |
| Cardiac FailureCardiac disorders | 51/6007 | 62/6012 |
| PneumoniaInfections and infestations | 58/6007 | 48/6012 |
| DeathGeneral disorders | 25/6007 | 30/6012 |
| Cardiac Failure CongestiveCardiac disorders | 24/6007 | 25/6012 |
| Cardiac Failure AcuteCardiac disorders | 14/6007 | 14/6012 |
| Atrial FibrillationCardiac disorders | 13/6007 | 10/6012 |
| Cardiac Failure ChronicCardiac disorders | 13/6007 | 8/6012 |
| CellulitisInfections and infestations | 11/6007 | 10/6012 |
| Urinary Tract InfectionInfections and infestations | 11/6007 | 11/6012 |
| Event | Rivaroxaban 10 mg or 7.5 mg | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 114/6007 | 147/6012 |
| HypertensionVascular disorders | 75/6007 | 93/6012 |
| DiarrhoeaGastrointestinal disorders | 69/6007 | 52/6012 |
| Age, Continuous(years) | Rivaroxaban 10 mg or 7.5 mg | Placebo | Total |
|---|---|---|---|
| Mean | 69.7 ± 10.06 | 69.7 ± 10.22 | 69.7 ± 10.14 |
| Sex: Female, Male(Participants) | Rivaroxaban 10 mg or 7.5 mg | Placebo | Total |
|---|---|---|---|
| Female | 2877 | 2858 | 5735 |
| Male | 3130 | 3154 | 6284 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban 10 mg or 7.5 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 499 | 482 | 981 |
| Not Hispanic or Latino | 5490 | 5510 | 11000 |
| Unknown or Not Reported | 18 | 20 | 38 |
| Race (NIH/OMB)(Participants) | Rivaroxaban 10 mg or 7.5 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 5 | 14 |
| Asian | 8 | 8 | 16 |
| Native Hawaiian or Other Pacific Islander | 128 | 123 | 251 |
| Black or African American | 71 | 57 | 128 |
| White | 5782 | 5808 | 11590 |
| More than one race | 6 | 9 | 15 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(Participants) | Rivaroxaban 10 mg or 7.5 mg | Placebo | Total |
|---|---|---|---|
| ARGENTINA | 120 | 122 | 242 |
| AUSTRALIA | 45 | 43 | 88 |
| AUSTRIA | 6 | 8 | 14 |
| BELARUS | 67 | 66 | 133 |
| BOSNIA-HERZEGOVINA | 298 | 299 | 597 |
| BRAZIL | 46 | 46 | 92 |
| BULGARIA | 714 | 714 | 1428 |
| CANADA | 21 | 22 | 43 |
| COLOMBIA | 70 | 70 | 140 |
| CROATIA | 135 | 135 | 270 |
| CZECH REPUBLIC | 115 | 116 | 231 |
| DENMARK | 3 | 4 | 7 |
| ESTONIA | 5 | 6 | 11 |
| GEORGIA | 880 | 882 | 1762 |
| GERMANY | 8 | 9 | 17 |
| GREECE | 66 | 65 | 131 |
| HUNGARY | 275 | 274 | 549 |
| ISRAEL | 55 | 56 | 111 |
| ITALY | 74 | 73 | 147 |
| LATVIA | 154 | 154 | 308 |
| LITHUANIA | 82 | 82 | 164 |
| MEXICO | 17 | 15 | 32 |
| NETHERLANDS | 8 | 9 | 17 |
| PERU | 33 | 32 | 65 |
| POLAND | 310 | 309 | 619 |
| PORTUGAL | 6 | 7 | 13 |
| PUERTO RICO | 0 | 1 | 1 |
| REPUBLIC OF MACEDONIA | 451 | 451 | 902 |
| ROMANIA | 162 | 162 | 324 |
| RUSSIAN FEDERATION | 571 | 571 | 1142 |
| SERBIA | 305 | 304 | 609 |
| SOUTH AFRICA | 103 | 102 | 205 |
| SPAIN | 192 | 191 | 383 |
| TURKEY | 35 | 35 | 70 |
| UKRAINE | 426 | 428 | 854 |
| UNITED KINGDOM | 4 | 4 | 8 |
| UNITED STATES | 145 | 145 | 290 |
Showing the first 100 of 617 sites across 37 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2014 to primary completion in Mar 2018, 49 months.
Results were first posted in Nov 2019, 1 year 8 months after primary completion. A results delay was requested in Mar 2019.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 49 months is above that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Janssen Research & Development, LLC →